Pharmaceutical Chloramphenicol Material Chloramphenicol

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Chloramphenicol
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Chloramphenicol
• Name: Chloramphenicol Powder
• Appearance: White Powder
• Colour: White
• Grade: Pharmaceutical Grade
• Assay: >99%
• Application: API
• Specific: COA
• Test Method: HPLC
• CAS: 56-75-7
• Mf: C11h12cl2n2o5
• MW: 323.12938
• Density: 1.547
• Melting Point: 149-153c
• Boiling Point: 644.9c at 760 Mmhg
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS- Chloramphenicol
• Origin: Xian
• Production Capacity: 1000kg/Month

Product Description

 Pharmaceutical Chloramphenicol Material Chloramphenicol

Product Description

Product Details

Product Name	Chloramphenicol
Appearance	Chloramphenicol  Powder
Assay	99%
MW	323.12938
MF	C11H12Cl2N2O5

Chloramphenicol exerts broad-spectrum antibacterial effects by inhibiting bacterial protein synthesis and is an important therapeutic drug for severe infections such as typhoid fever and meningitis. However, its bone marrow suppression and neonatal toxicity risks limit its long-term clinical use, requiring strict monitoring of blood routine and avoidance of neonatal exposure. It can be used for gene screening and tumor metabolism research in scientific research.

Application&Function

The pharmacological effects of Chloramphenicol
1. Pharmacological mechanism of action
Antibacterial effect:
By inhibiting the peptidyl transferase activity of the 50S ribosomal subunit in bacteria, blocking peptide chain extension, and thus inhibiting bacterial protein synthesis, it has a broad-spectrum antibacterial effect.
It is effective against both Gram positive bacteria (such as pneumococcus and staphylococci) and Gram negative bacteria (such as typhoid bacilli, influenza bacilli, and Escherichia coli), and also has inhibitory effects on chlamydia and rickettsia.
Other mechanisms:
Inhibit the stability of hypoxia inducible factor-1 alpha (HIF-1 alpha) in hypoxic cells and reduce the mRNA expression levels of ( ) and glucose transporter 1.
2. Indications
Infectious diseases:
Febrile and paratyphoid fever (one of the preferred medications).
Bacterial meningitis (especially infections caused by Haemophilus influenzae and meningococcal bacteria).
Severe respiratory infections (pneumonia, pertussis).
Eye infections (such as conjunctivitis, keratitis) and skin and soft tissue infections.
Special pathogen infection:
Rickettsia disease (such as typhus), anaerobic bacterial infection (adjuvant therapy).
3. Pharmacokinetic characteristics
Absorption and distribution:
Oral absorption is fast, reaching peak blood drug concentration within 2 hours; Widely distributed in tissues and body fluids throughout the body, the concentration in cerebrospinal fluid can reach 30% -50% of blood concentration.
The half-life of plasma is about 2.5 hours, but due to insufficient metabolic capacity in newborns, the half-life is significantly prolonged.
4. Adverse reactions and risks
Hematological toxicity:
Bone marrow suppression (dose-dependent, such as anemia and leukopenia) and aplastic anemia (rare but fatal).
Gray baby syndrome:
Newborns may suffer from cyanosis, circulatory failure, and even death due to insufficient liver metabolic capacity.
Other: Gastrointestinal reactions (nausea, diarrhea), allergic reactions (rash).
5. Drug resistance
Bacteria can produce chloramphenicol acetyltransferase (CAT) inactivating drugs or alter the structure of ribosome targets through genetic mutations.
Drug resistance is more common in Escherichia coli, Shigella, and other bacteria, while the resistance rate of typhoid bacilli is relatively low.

 

Specification